Recommendation of the President – Padcev (enfortumab vedotin)
On 25 July 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 97/2025 on the appraisal of drug Padcev (enfortumab vedotin) under the drug program “Treatment of patients with urothelial cancer (ICD-10: C61, C65, C66, C67, C68)”